Medical oncologist with focus on kidney cancer, immunotherapies and the tumor microenvironment. Views expressed are my own. #kidneycancer #immunotherapy
Dallas, TX
- Tweets 3,464
- Following 687
- Followers 4,105
- Likes 3,201
Absolutely no surprise here! 🎉👏 So well deserved @brian_rini & @tompowles1
A huge fan of @Uromigos and the brilliant Tom and Brian❤️ Their passion, wit, and ability to bring the global GU oncology community together for insightful, engaging, and entertaining conversations make this podcast truly special and unique with a 🌏 footprint!
Congratulations on this wonderful recognition! 🎙️🏆
@LosUromigos @uromigosjapan @OncoAlert @montypal @neerajaiims @Silke_Gillessen @PGrivasMDPhD @DrChoueiri @ChrisSweens1 @kalasri3
@myESMO @UroDocAsh
2
7
507
This is a game changer!!
45% durable ORRs at higher dose levels.
READY for prime time and will change early treatment lines.
As excited as when I first saw PD1 results in RCC.
This will transform front lines and cure more patients.
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
1
11
41
2,104
ENPP3 x CD3 ! Seismic Shift to come !!
Let’s end using non IO drugs in the frontline and focus on CURE!
Well well well…
This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape!
45% response in heavily pretreated pts. Highly impressive!
Needs to move into frontline combinations! Congrats @montypal + colleagues
1
22
766
Well well well…
This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape!
45% response in heavily pretreated pts. Highly impressive!
Needs to move into frontline combinations! Congrats @montypal + colleagues
1
24
67
9,508
Impressive ! Congrats !
Huge congrats to Drs. @EHeath4100 & @EAntonarakis on the new Mayo/UMN #ProstateCancer SPORE grant from @NCIDCTD! 🎉 A well-deserved recognition of your leadership & a major step forward for mCRPC/APMR precision Rx research Link👉l1nq.com/mwvzc8f @PCFnews @urotoday
3
663
Congrats Neeraj @neerajaiims !!
Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!
6
790
Hans Hammers retweeted
Our melanoma team recently treated its first patient with advanced melanoma using tumor-infiltrating lymphocyte (TIL) therapy.
Congratulations to the entire team on this important achievement!
Learn more about TIL therapy: bit.ly/3UDhnvu.
1
2
13
653
Hans Hammers retweeted
Congratulations to Dr. Yousef Zakharia of Mayo Clinic, recipient of the 2026 Outstanding Advocacy Leadership Award.
This award recognizes individuals whose leadership and dedication to advocacy have helped advance kidney cancer research and improve the lives of patients. Through his commitment to collaboration and advocacy, Dr. Zakharia has been an important voice for continued progress in the kidney cancer community.
Congratulations on this well-deserved honor, and thank you for your continued leadership.
#KCRS26 #AcceleratingCures
1
4
22
3,839
Hans Hammers retweeted
Congratulations to the 2026 AACR–KidneyCAN Innovation & Discovery Grant recipients!
This year's awardees are:
• Jessica Spinelli, PhD, University of Massachusetts Chan Medical School
• Maralice Conacci-Sorrell, PhD, UT Southwestern Medical Center
• Ritesh Kotecha, MD, Memorial Sloan Kettering Cancer Center
These grants support innovative, high-impact research with the potential to transform our understanding of kidney cancer and accelerate the development of new treatments.
Congratulations to this exceptional group of investigators on this well-deserved recognition!
#KCRS26 #AcceleratingCures
1
8
13
2,170
Hans Hammers retweeted
Register now for our 2026 Oncology Year in Review CME! bit.ly/4wVJHHR
This program will provide participants with the latest information available, as presented at the @ASCO meeting, @myESMO meeting, and other meetings that took place in 2026, from our experts.
1
3
5
938
Hans Hammers retweeted
Clinical trials have helped keep me alive for more than a decade. I know firsthand that finding the right trial at the right time can change everything.
That’s why I’m excited about @KidneyCAN’s new Clinical Trial Navigator, helping kidney cancer patients more easily find trials that could provide their next option.
Patients shouldn’t have to become experts at searching for clinical trials while fighting cancer. We need to make it easier to find the science, understand the options and know what to do next.
For some of us, a clinical trial isn’t just research.
It’s hope. It’s another option. It’s more time.
kidneycancertrials.org
Thank you @kidneycan for launching a tool that helps all kidney cancer patients. #ClinicalTrials
9
17
1,995
Hans Hammers retweeted
What an incredible two days.
#KCRS26 brought together researchers, clinicians, industry leaders, advocates, and patient representatives from around the world to share discoveries, challenge ideas, build collaborations, and inspire the next generation of #KidneyCancer research.
From groundbreaking keynote presentations and innovative abstract sessions to Rock the Run, Posters & Prosecco, and countless conversations in the hallways, every moment reflected the passion and dedication of this remarkable community.
Thank you to everyone who joined us, whether in Boston or virtually. Together, we're accelerating progress toward better treatments and brighter futures for people affected by kidney cancer.
We'll see you next year.
#AcceleratingCures
3
9
445
Volumetric is the Key!
Just the longest diameter may mean nothing, deflating a “balloon” may do little to the longest diameter but yet you may have reduced tumor burden by 90+% and might be cured!
Response assessment in metastatic kidney cancer on ipi/nivo is hard: over half of patients show atypical patterns, and readers disagree. An automated volumetric iRECIST tool nearly doubled reader agreement.
🎯 Interobserver agreement κ 0.34 → 0.67 with AI assist
🔬 75 mRCC patients, lesion tracking accuracy 0.98
🔍 Single center, feasibility, not yet prospectively validated
If it holds, the value is consistency: hypothesis-generating. Excited to see more tools in RECIST imaging assessment.
👉bit.ly/Kraaijveld-iRECIST-mR…
#KidneyCancer #GUonc #AIinMedicine
3
6
1,015
Hans Hammers retweeted
The true legacy of mentorship is not one successful investigator, but generations of them. @DrChoueiri impact on the global RCC community is extraordinary.
#AcceleratingCures #KCRS26
@kidneycan @DrChoueiri @HHammersMD @IKCCorg @advocatekidneys @DrRanaMcKay @NazliDizman @MikeSerzanMD @crisbergerot @Uromigos @OncoAlert @OpenMedicineHQ @montypal @arihakimi @TiansterZhang @AlbigesL @ReneeSaliby @VincentWenxinXu @yekeduz_emre @g_develasco @FabioSchutz78 @lalaniMD @Dominick_Bosse @DrRanaMcKay @maxinesun @BraunMDPhD
16
37
1,673
Hans Hammers retweeted
Dual PD-1/VEGF blockade and cooperative binding provide a compelling biological rationale for ivonescimab.
The key questions are not whether the mechanism is attractive, but: Does it translate into better efficacy?
Ultimately, clinical outcomes will determine whether this approach changes practice.
#AcceleratingCures #KCRS26
@kidneycan @DrChoueiri @HHammersMD @IKCCorg @advocatekidneys @DrRanaMcKay @NazliDizman @MikeSerzanMD @crisbergerot @Uromigos @OncoAlert @OpenMedicineHQ @montypal @arihakimi @TiansterZhang @AlbigesL @ReneeSaliby @VincentWenxinXu
1
10
23
1,215
Thank you ! 🙏
Let us know how to make it even better. @kidneycan would love to have feedback/suggestions.
@KidneyCAN4KCRS
@HMcclurd
1
2
4
750
Hans Hammers retweeted
Great AACR 2026 highlights from @TiansterZhang at #KCRS26 on mechanisms shaping RCC therapy.
🔬 NEO-811 (ARNT/HIF1β degrader) retains activity even in HIF2α resistant tumors, degrading the obligate dimerization partner instead of HIF2α itself
🧫 CBM-588 correlative data shows less T-cell exhaustion with gut microbiome modulation added to ipi-nivo
Resistance and the microbiome, two fronts worth watching in RCC.
#RCC #KidneyCancer #GUonc #KCRS26 @kidneycan
8
11
770
Hans Hammers retweeted
For the first time: plenary session during #KCRS26! Totally new data presented by Drs Powles, Mckay and Jones
8
33
2,869
Thank you for all that you do @CJSTRAV3 for the kidney cancer community and @kidneycan !
That’s a wrap: #KCRS2026. I am filled with gratitude and hope. Ten years ago, I never imagined I’d be here, living with Stage IV kidney cancer, surrounded by so many brilliant people who have dedicated their lives to giving patients like me a future.
Thank you, @KidneyCAN, for your relentless leadership in bringing together patients, caregivers, researchers, clinicians, industry, and advocates to challenge the status quo and accelerate progress. Every breakthrough starts with people willing to work together.
For patients like me, KCRS isn’t just another conference. It’s a true reminder that hope is real, progress is happening, and we’re not done yet. Thank you to everyone helping turn a diagnosis into more tomorrows. The race is far from over. Let’s GO!! 👊👊❤️☘️
1
5
674